RESEARCH ARTICLE

Radiofrequency ablation using internally cooled wet electrodes in bipolar mode for the treatment of recurrent hepatocellular carcinoma after locoregional treatment: A randomized prospective comparative study

Jae Won Choi¹,², Jeong Min Lee¹,²,³*, Dong Ho Lee¹,², Jung-Hwan Yoon⁴,⁵, Yoon Jun Kim⁴,⁵, Jeong-Hoon Lee⁴,⁵, Su Jong Yu⁴,⁵, Eun Ju Cho⁴,⁵

¹ Department of Radiology, Seoul National University Hospital, Seoul, Korea, ² Department of Radiology, Seoul National University College of Medicine, Seoul, Korea, ³ Institute of Radiological Medicine, Seoul National University Medical Research Center, Seoul, Korea, ⁴ Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, ⁵ Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea

* jmsh@snu.ac.kr

Abstract

Objective

This study aimed to compare the efficacy between bipolar radiofrequency ablation (RFA), using twin internally cooled wet (TICW) electrodes, and switching monopolar RFA, using separable clustered (SC) electrodes, in the treatment of recurrent hepatocellular carcinoma (HCC) after locoregional treatment.

Materials and methods

In this single-center, two-arm, parallel-group, randomized controlled study, we performed a 1:1 random allocation on eligible patients with recurrent HCC after locoregional treatment, to receive TICW-RFA or SC-RFA. The primary endpoint was the minimum diameter of the ablation zone per unit ablation time. Secondary endpoints included other technical parameters, complication rate, technical success and technique efficacy, and clinical outcomes.

Results

Enrolled patients were randomly assigned to the TICW-RFA group (n = 40) or SC-RFA group (n = 37). The two groups did not show significant differences in the primary endpoint, the minimum diameter of the ablation zone per unit ablation time was 2.71 ± 0.98 mm/min and 2.61 ± 0.96 mm/min in the TICW-RFA and SC-RFA groups, respectively (p = 0.577). Total RF energy delivery (11.75 ± 9.04 kcal vs. 22.61 ± 12.98 kcal, p < 0.001) and energy delivery per unit time (0.81 ± 0.49 kcal/min vs. 1.45 ± 0.42 kcal/min, p < 0.001) of the TICW-RFA group were less than those of the SC-RFA group. No procedure-related death or major complications occurred. Technical success was achieved in all patients in both groups, and
technique efficacy rates were 100% (46/46) in the TICW-RFA group and 95.0% (38/40) in the SC-RFA group (p = 0.213). The 1-year and 2-year cumulative LTP rates were 11.8% and 24.2%, respectively, in the TICW-RFA group, and 8.6% and 18.1%, respectively, in the SC-RFA group (p = 0.661).

Conclusion

In this single-center randomized controlled study from a Korean tertiary referral hospital, TICW-RFA demonstrated similar therapeutic efficacy and safety profile for recurrent HCC after locoregional treatment compared with SC-RFA.

Trial registration

ClinicalTrials.gov (NCT03806218)

Introduction

Radiofrequency ablation (RFA) is currently recommended as an intended curative treatment for very early or early-stage hepatocellular carcinoma (HCC) in patients who are not surgical candidates according to guidelines from Europe, Asia, and North America [1–3]. Similarly, several previous studies also demonstrated that RFA could be used as a minimally invasive treatment modality for recurrent HCC [4–6]. However, a significant drawback of RFA has been the higher rate of local tumor progression (LTP) than that of surgical resection, for the treatment of HCC. This is probably due to the unreliable capability of RFA in producing sufficient ablative margin in a range of 5–10 mm [7–11]. Furthermore, in cases of recurrent HCC after locoregional treatment, LTP rates after RFA have been reported as being even higher than that in treatment-naïve HCC [12–15]. This could be attributed to tissue heterogeneity, indistinct tumor margin, or various off-target microenvironmental effects of previous treatment, leading to more invasive biological behavior of recurrent tumors [16–21]. Among them, heterogeneous tissue composition in recurrent tumors, including necrosis, fibrosis, adhesion, inflammation, and vaporized area after transcatheter arterial chemoembolization (TACE) or RFA may result in technical difficulty in delivering sufficient RF energy throughout the viable tumor, which ultimately may fail to kill tumor cells in the target tumor.

Until now, there have been various investigational approaches to efficiently create an ablation zone with a lethal thermal dose (> 60°C), enough to achieve sufficient ablative margin around the target tumor. These include modern high-powered RF devices with multiple electrodes, using switching monopolar [22, 23] or multipolar RFA [24, 25], a microwave ablation system [26–28], and combination with transarterial embolization or drugs [29–32]. Among them, in many institutes of Korea, including our hospital, two types of commercially available multiple-electrode systems have been used for the treatment of HCC: bipolar RFA, using twin internally cooled wet (TICW) electrodes (CWTN-T, RF Medical, Seoul, Korea) and a single-generator unit (M-3004, RF Medical); and switching monopolar RFA, using separable clustered (SC) electrodes with three active tips (Octopus, STARmed, Goyang, Korea) and a dual-generator unit (VIVA Multi, STARmed) [33]. Considering the tissue heterogeneity in recurrent tumors, we assumed that combined use of bipolar mode and saline perfusion in TICW-RFA, might provide additive value to the ablative efficiency by increasing current density between the electrode, and improving both electric and thermal conductivity [34].
Therefore, we conducted a randomized prospective comparative study between TICW-RFA and SC-RFA to compare their efficacy in the treatment of recurrent HCC after locoregional treatment.

Materials and methods

Study design

This single-center, two-arm, parallel-group, randomized controlled study was approved by the institutional review board of Seoul National University Hospital (#1502-105-652). After the approval by the institutional review board on April 13, 2015, participant recruitment and investigation were conducted at Seoul National University Hospital. All patients provided written informed consent at study enrollment. Patients underwent a 1:1 random assignment to the TICW-RFA or SC-RFA group. We applied a blocked randomization method with mixed block sizes 4 and 6, using a web-based allocation table, generated ahead of the study and managed by our institution’s medical research collaboration center. Randomization was stratified by the length of the active tip of the RFA electrode (2 cm or 2.5 cm), as the length of the active tip is determined according to the size of the index tumor. Study participants and those assessing outcomes were blinded to group assignment.

Although public registration before participant recruitment is recommended for a clinical trial, this study was initially recorded at our institutional clinical study database. We additionally registered our study at ClinicalTrials.gov (NCT03806218) for publication after it ended. The authors confirm that all ongoing and related trials for this intervention are registered. RF Medical Co., Ltd. (Seoul, Korea) provided a research grant for this study. The authors had complete control of the data and information at all times.

Patients

From May 19, 2015, to July 4, 2016, one of the authors (J.M.L.) recruited those who met the following inclusion and exclusion criteria among patients who were referred to our department for RFA, as treatment for intrahepatic recurrent HCC after locoregional treatment (Fig 1). Inclusion criteria were as follows: (a) age 20 to 80 years, (b) radiologic or pathologic diagnosis of intrahepatic recurred HCC, including both LTP and intrahepatic distant recurrence (IDR) after locoregional treatment, and (c) HCC nodules measuring 1 cm or larger, but smaller than 5 cm. Exclusion criteria were as follows: (a) more than three HCC nodules, (b) tumors with major vascular invasion or abutment to the central portal or hepatic vein with a diameter >5 mm, (c) extrahepatic metastasis, (d) Child-Pugh class C, and (e) severe coagulopathy (platelet cell count of less than 50,000 cells/mm³ or prothrombin time international normalized ratio (PT-INR) prolongation of more than 50%).

RFA procedure

One experienced radiologist (J.M.L.), with 20 years of experience in RFA, conducted all RFA procedures on an inpatient basis, assisted by one radiology fellow or resident. Evaluation of feasibility and planning of RFA procedures were performed based on pre-procedural CT or MRI studies and fusion imaging techniques between real-time US imaging and reference CT or MRI images [35]. Before percutaneous electrode insertion, intravenous conscious sedation and local anesthesia were induced. Throughout the procedure, patients underwent continuous monitoring of vital signs, electrocardiography, and oxygen saturation levels.

In both the TICW-RFA and SC-RFA groups, RFA was performed based on the ablation protocols used in routine clinical practice. In the TICW-RFA group, bipolar RFA was
performed using TICW electrodes (Fig 2A; CWTN-T, RF Medical, Seoul, Korea) and a single-generator unit (M-3004, RF Medical). Chilled 0.9% isotonic saline was circulated inside the electrode, 99% for cooling the electrode, and 1% for saline infusion into the surrounding tissue [36]. The SC-RFA group underwent switching monopolar RFA, using SC electrodes with three active tips (Fig 2B; Octopus, STARmed, Goyang, Korea) and a dual-generator unit (VIVA Multi, STARmed). The details of the equipment and working process of the RFA systems were the same as described in previous studies [36–39].

The operator chose the length of the active tip, based on the size of the index tumor. In general, the operator used electrodes with a 2-cm active tip for a tumor smaller than 2 cm, and those with a 2.5-cm active tip for a larger one [39]. The fusion imaging technique was applied for initial targeting of the index tumor, to improve tumor visibility and overall technical feasibility [40], and also for intraprocedural monitoring of the ablation [35, 41]. If needed, the operator instilled a 5% dextrose solution into the perihepatic space for artificial ascites, to improve the sonic window, or to prevent adjacent organ injury while treating subcapsular tumors [42].

**Evaluation of procedure and follow-up**

Multiphasic contrast-enhanced CT studies were conducted immediately after all the RFA procedures for assessment of ablation size, post-procedural complications, and technical success based on the reporting criteria suggested by the International Working Group on Image-guided Tumor Ablation [43]. The zone of ablation was defined as the non-enhancing hypoattenuating area on the portal phase CT [44], and diameters and volume of the ablation zone were measured. Assuming that the ablation zone was spherical as described in the previous
study [22], the ablation volume and the effective ablation volume were measured as follows:

\[
\text{Ablation volume} = \frac{\pi \times D_{\text{max}} \times D_{\text{min}} \times D_v}{6}
\]

\[
\text{Effective ablation volume} = \frac{\pi \times D_{\text{min}}^3}{6}
\]

where \(D_{\text{max}}\) and \(D_{\text{min}}\) are the longest and shortest diameters of the ablation zone on the axial image with the largest ablation area, and \(D_v\) is the longest vertical diameter of the ablation zone on the coronal reconstructed image. In addition to size measurements, ablation time and amount of energy delivery were also recorded.

We evaluated major complications, such as post-procedural events that extended the amount of care or prolonged the stay in the hospital, according to the guidelines of the Society of Interventional Radiology [43, 45].

Based on the standardization of terminology and reporting criteria proposed by the International Working Group on Image-guided Tumor Ablation [43], we defined technical success as an ablation that completely covered the index tumor with an ablative margin greater than or equal to 5 mm at the immediate post-procedural CT. Any irregular or nodular peripheral enhancement at the ablation margin, was regarded as indicating an unablated residual tumor and a treatment failure [46]. Patients with an initially unsuccessful RFA underwent an additional ablation in less than 24 hours during the same hospital stay. Technique efficacy was evaluated as complete coverage of the ablation of the index tumor, with no nodular arterial enhancement at the ablation zone on a 1-month follow-up CT or MRI scan [37, 43, 47].
For 2 years after RFA, patients underwent contrast-enhanced CT or MRI every 3 months for the detection of LTP as well as IDR and extrahepatic metastasis (EM) [37, 43]. LTP was defined as the appearance of tumor foci at the periphery of the ablation zone, after at least one contrast-enhanced follow-up study had recorded technical success and technique efficacy according to imaging criteria [43]. Recurrence-free survival (RFS) time was defined as the duration of the follow-up until LTP, IDR, EM, or death occurred. Moreover, among recurrence cases, we defined aggressive intrasegmental recurrence (AIR) as the simultaneous multinodular (three or more) recurrence or infiltrative tumor recurrence in the treated segment of the liver, at least 6 months after a disease-free state following RFA [48].

**Outcomes**

The primary endpoint was Dmin per unit time. Secondary endpoints were as follows: other technical parameters including size of the ablation zone, ablation time, and energy delivery; complication rate; technical success; technique efficacy; and clinical outcomes including LTP rates, LTP-free survival, and RFS.

**Statistical analysis**

We calculated the sample size using an approximation of the difference in the primary endpoint between the two groups, a two-sided type I error of 0.05, and a power of 0.8. We estimated that the difference in Dmin per unit time between the two groups would be 0.63 based on a previous study comparing the bipolar RFA and the switching monopolar RFA [37]. The minimum sample size was calculated to be 41 patients in each group, and assuming the drop rate of 5%, we decided to enroll 43 patients for each group. Technical parameters, technical success, technique efficacy, and LTP rates were analyzed with per-nodule data. Complications and other clinical outcomes were analyzed with per-patient data. Categorical variables were compared using the chi-squared test or Fisher’s exact test, as appropriate. Continuous variables that did not pass the Shapiro-Wilk normality test were compared using the Mann-Whitney test. Other continuous variables were compared using the independent t-test or Welch test, as appropriate. We used the Kaplan-Meier method for survival analysis and the log-rank test for assessing differences between the survival curves. We performed multivariate Cox proportional hazards regression analysis using the group allocation and the baseline characteristics to evaluate the relative risk factors associated with LTP and RFS. A p-value of less than 0.05 was considered a significant difference. Statistical analyses were conducted using MedCalc Statistical Software version 17.6 (MedCalc Software bvba, Ostend, Belgium).

**Results**

**Patients**

From May 19, 2015, to July 4, 2016, 86 patients were initially included in the study and underwent 1:1 randomization, with 43 patients in the TICW-RFA and 43 patients in the SC-RFA group. Among 86 patients, 9 patients were excluded from the study: withdrawal of consent (n = 1), difficult location (abutting diaphragm) (n = 2), failed sedation (n = 2), biopsy-confirmed cholangiocarcinoma (n = 1), diagnosed extrahepatic metastasis on immediate post-RFA CT (n = 2), and more than 3 nodules detected on the day of procedure (n = 1). The final study population was 77 patients: 40 patients with 46 nodules treated with TICW-RFA and 37 patients with 40 nodules treated with SC-RFA (Fig 1). The baseline characteristics of the study population are shown in Table 1. The proportion of LTP in the recurred target tumors did not show a significant difference between the TICW-RFA group and the SC-RFA group (78.3% vs.
We defined early and late recurrences as those that had recurred within 12 months or after 12 months after the previous locoregional treatment [49]. The proportion of early recurrences was not significantly different between the TICW-RFA group and the SC-RFA group (72.5% vs. 56.8%, respectively, p = 0.148). Both groups underwent various previous locoregional treatments, including RFA, TACE, and percutaneous ethanol injection therapy (PEIT), and the combination of different modalities showed the highest proportion in both groups. The TICW-RFA group had a higher PT INR (1.12 ± 0.09 vs. 1.06 ± 0.08, p = 0.002) and a trend toward less subcapsular tumors (23.9% vs. 42.5%, p = 0.068) than the SC-RFA group. Otherwise, there were no significant differences between the two groups concerning demographic features, tumor size and number, serum AFP level, and liver function.

**Technical parameters**

The TICW-RFA group and the SC-RFA group did not show significant differences in the primary endpoint, Dmin per unit time (2.71 ± 0.98 mm/min vs. 2.61 ± 0.96 mm/min, p = 0.577),

### Table 1. Baseline characteristics of the study population.

|                      | TICW-RFA (n = 40) | SC-RFA (n = 37) | P-value |
|----------------------|-------------------|----------------|---------|
| Age                  | 63.8 ± 9.9        | 64.2 ± 10.1    | 0.883   |
| M/F ratio            | 34/6              | 31/6           | 0.884   |
| Single HCC, %        | 87.5 (35/40)      | 91.9 (34/37)   | 0.713   |
| Size, cm             | 1.57 ± 0.54       | 1.72 ± 0.78    | 0.496   |
| Used active tip, %   |                   |                | 0.906   |
| 2 cm                 | 50.0 (20/40)      | 48.6 (18/37)   |         |
| 2.5 cm               | 50.0 (20/40)      | 51.4 (19/37)   |         |
| Subcapsular location, % | 23.9 (11/46) | 42.5 (17/40)   | 0.068   |
| AFP, ng/ml           | 20.4 ± 34.8       | 77.1 ± 218.8   | 0.625   |
| Child-Pugh class, %  |                   |                | 0.202   |
| A                    | 87.5 (35/40)      | 97.3 (36/37)   |         |
| B                    | 12.5 (5/40)       | 2.70 (1/37)    |         |
| Albumin              | 3.91 ± 0.52       | 4.05 ± 0.41    | 0.184   |
| Bilirubin            | 0.89 ± 0.59       | 0.69 ± 0.48    | 0.069   |
| PT INR               | 1.12 ± 0.09       | 1.06 ± 0.08    | 0.002   |
| Platelet, x 1000/mm³ | 131.7 ± 71.4      | 135.3 ± 43.0   | 0.169   |
| Type of recurrence, %|                   |                | 0.384   |
| LTP                  | 78.3 (36/46)      | 70.0 (28/40)   |         |
| IDR                  | 21.7 (10/46)      | 30.0 (12/40)   |         |
| Onset of recurrence, %|                  |                | 0.148   |
| Early (< 12 mo)      | 72.5 (29/40)      | 56.8 (21/37)   |         |
| Late (≥ 12 mo)       | 27.5 (11/40)      | 43.2 (16/37)   |         |
| Previous treatment modality, % |  | | |
| RFA                  | 5.0 (2/40)        | 13.5 (5/37)    |         |
| TACE                 | 45.0 (18/40)      | 32.4 (12/37)   |         |
| PEIT                 | 0.0 (0/40)        | 2.7 (1/37)     |         |
| ≥ 2 modalities       | 50.0 (20/40)      | 51.4 (19/37)   |         |

Note.—LTP = local tumor progression, IDR = intrahepatic distant recurrence.

1Number of patients,
2Type of recurrence, tumor size, and frequency of subcapsular tumors were measured on a per-nodule basis. Plus-minus values are means ± standard deviations.

https://doi.org/10.1371/journal.pone.0239733.t001

70.0%, respectively, p = 0.384). We defined early and late recurrences as those that had recurred within 12 months or after 12 months after the previous locoregional treatment [49]. The proportion of early recurrences was not significantly different between the TICW-RFA group and the SC-RFA group (72.5% vs. 56.8%, respectively, p = 0.148). Both groups underwent various previous locoregional treatments, including RFA, TACE, and percutaneous ethanol injection therapy (PEIT), and the combination of different modalities showed the highest proportion in both groups. The TICW-RFA group had a higher PT INR (1.12 ± 0.09 vs. 1.06 ± 0.08, p = 0.002) and a trend toward less subcapsular tumors (23.9% vs. 42.5%, p = 0.068) than the SC-RFA group. Otherwise, there were no significant differences between the two groups concerning demographic features, tumor size and number, serum AFP level, and liver function.
or in any other ablation size-related variables (Table 2) or ablation time (13.92 ± 4.96 min vs. 15.60 ± 6.80 min, p = 0.441). In the TICW-RFA group, total RF energy delivery (11.75 ± 9.04 kcal vs. 22.61 ± 12.98 kcal, p < 0.001) and energy delivery per unit time (0.81 ± 0.49 kcal/min vs. 1.45 ± 0.42 kcal/min, p < 0.001), were smaller than in the SC-RFA group.

### Complications

No procedure-related death occurred. There were no major complications requiring an increased level of care or more extended hospital stay. One patient from each group had a small amount of pneumothorax, and one patient in the TICW-RFA group showed a small amount of hematoma without evidence of active bleeding. All three patients underwent close observation and were discharged after confirming the decrease of such findings at short-term follow-up CT.

### Technical success, technique efficacy, and clinical outcomes

All patients in both groups showed a technical success. Moreover, at a 1-month follow-up imaging study, the technique efficacy rates were 100% (46/46) in the TICW-RFA group and 95.0% (38/40) in the SC-RFA group (p = 0.213). At the time of the analysis, patients were observed for a mean follow-up of 20.5 months ± 8.3 (median, 23.6 months).

Out of 46 recurrent HCC nodules treated with TICW-RFA, and 38 with SC-RFA, in which technique efficacy was achieved, cumulative LTP rates at 1 year and 2 years of follow-up were 11.8% and 24.2%, respectively, in the TICW-RFA group, and 8.6% and 18.1%, respectively, in the SC-RFA group (p = 0.661) (Fig 3A). In a subgroup analysis according to the type of recurrence, among 64 nodules that presented as LTP, cumulative LTP rates at 1 year and 2 years after RFA were 15.5% and 25.5%, respectively, in the TICW-RFA group (n = 36) and 12.2% and 26.1%, respectively, in the SC-RFA group (n = 27) (p = 0.848) (Fig 3B).

The 1-year and 2-year LTP-free survival rates of 40 patients in the TICW-RFA group were 86.5% and 75.2%, respectively, and those of 35 patients in the SC-RFA group were 91.1% and 81.3%, respectively, (p = 0.673) (Fig 4A). The 1-year and 2-year RFS rates of the patients were

### Table 2. Comparison of technical parameters between TICW-RFA and SC-RFA groups.

| Parameter                        | TICW-RFA (n = 46)     | SC-RFA (n = 40)     | P-value |
|----------------------------------|-----------------------|---------------------|---------|
| Dmin/time, mm/min                | 2.71 ± 0.98           | 2.61 ± 0.96         | 0.577   |
| Dmin/energy, mm/kcal             | 4.37 ± 2.65           | 1.95 ± 0.91         | < 0.001 |
| Dmin, cm                         | 3.40 ± 0.66           | 3.58 ± 0.83         | 0.254   |
| Dmax, cm                         | 4.84 ± 0.92           | 5.29 ± 1.22         | 0.057   |
| Dv, cm                           | 3.80 ± 1.03           | 4.21 ± 1.20         | 0.169   |
| Ablation time, min               | 13.92 ± 4.96          | 15.60 ± 6.80        | 0.441   |
| Energy, kcal                     | 11.7 ± 9.0            | 22.6 ± 13.0         | < 0.001 |
| Energy/time, kcal/min            | 0.81 ± 0.49           | 1.45 ± 0.42         | < 0.001 |
| Ablation volume, cm³             | 35.24 ± 18.50         | 46.12 ± 31.15       | 0.222   |
| Ablation volume/time, cm³/min    | 2.64 ± 1.22           | 3.08 ± 1.75         | 0.387   |
| Effective ablation volume, cm³   | 22.77 ± 12.26         | 28.02 ± 21.31       | 0.637   |
| Effective ablation volume/time, cm³/min | 1.71 ± 0.87          | 1.88 ± 1.32         | 0.962   |

Note.—Dmax, Dmin = longest and shortest diameters of the largest ablation zone on axial plane, Dv = longest vertical diameter of the ablation zone on the coronal plane.

†Number of HCC nodules. Plus-minus values are means ± standard deviations.
69.6% and 40.8%, respectively, in the TICW-RFA group and 53.7% and 34.7%, respectively, in the SC-RFA group (p = 0.321) (Fig 4B). Moreover, multivariate Cox proportional hazard regression showed that there was no significant prognostic factor for LTP-free survival and only the size of the largest tumor (>1.5 cm; hazard ratio, 2.22; 95% confidence interval, 1.21–4.09; p = 0.010) was a significant prognostic factor for RFS. No AIR occurred in the TICW-RFA group, but one patient in the SC-RFA group developed AIR 19.5 months after the RFA. One patient in the TICW-RFA group died of uncontrolled esophageal variceal bleeding 21.9 months after the RFA procedure.

Discussion

The present study aimed to compare the two commercially available multiple-electrode RFA systems in Korea: the TICW-RFA and the SC-RFA. From a technical point of view, our study demonstrated that the TICW-RFA group and the SC-RFA group did not show significant differences in the primary endpoint, Dmin per unit time (2.71 ± 0.98 mm/min vs. 2.61 ± 0.96 mm/min, p = 0.577) or ablation time (13.92 ± 4.96 min vs. 15.60 ± 6.80 min, p = 0.441) in patients with recurrent HCCs after locoregional treatments. There were no major complications that involved an elevated level of care or hospital stay in both groups, and they showed high technical success and technique efficacy rates. Therefore, from a clinical point of view, both the TICW-RFA and the SC-RFA were safe and comparably effective treatment choices for the treatment of intrahepatic recurrence of HCC. Our study results regarding Dmin per
unit time were discrepant with the results of previous preclinical and clinical studies where RFA, using ICW electrodes, proved more effective in creating large ablation zones [25, 37, 50, 51]. This discrepancy between the previous study and this study, could be mainly attributed to relatively small-sized tumors (average size <2 cm), which may have led to underestimating the theoretical ablative capacities of the two RFA systems and the different number of electrodes between TICW RFA (n = 3) and SC-RFA (n = 2) groups. Nevertheless, the insignificant difference in ablation volumes, despite the geometric disadvantage of using two electrodes, and the lower total RF energy in the TICW-RFA group in our study, supports the better heat-producing efficiency of bipolar RFA with ICW electrodes [25, 37, 50, 51]. In other words, the benefit of bipolar RFA, using TICW in electrical and thermal conductance, compared with switching monopolar RFA, could be canceled out by the negative impact of fewer numbers of active heating sources during the procedure. Furthermore, although there was no difference in major complications between the two groups, there might be a theoretical increased risk of complications, related to electrode insertion, when a higher number of electrodes were used for RFA.

In addition, the 1-year and 2-year cumulative LTP rates in our study were 11.8% and 24.2%, respectively, in the TICW-RFA group and 8.6% and 18.1%, respectively, in the SC-RFA group (p = 0.661); the estimated 2-year LTP-free survival rates for both groups were 75.2% and 81.3% (p = 0.673), respectively. Also, multivariate Cox proportional hazard regression revealed the size of the largest tumor (>1.5 cm; hazard ratio, 2.22; 95% confidence interval, 1.21–4.09; p = 0.010) was the only significant prognostic factor for RFS, which means tumors measuring >1.5 cm have 2.22 times higher risk of overall recurrence than those measuring ≤1.5 cm. The similar LTP rates in the two groups could be attributed to the result that the two groups did not show a significant difference in ablation volumes. Creating a large ablation volume is closely related to a sufficient ablative margin, which is one of the most important factors for local tumor control of HCC [10]. Local tumor control rates in our study were lower than those of RFA for initial HCC (2-year LTP rate, 7%–10%) [38, 39, 52, 53], and somewhat lower than those reported in some previous studies on RFA for recurrent HCC (2-year LTP rate, 10%–25%) [6, 12]. This result was perhaps due to the heterogeneity of our study population, consisting of patients who underwent higher numbers, and various types of previous locoregional treatments. Various off-target effects of locoregional treatments may contribute to the more aggressive potential of recurrent tumors [16–18, 20, 21, 54]. Although RFA has been suggested as a minimally invasive and effective treatment option for recurrent HCC [4–6], the 2-year cumulative LTP rates and RFS rates are reported to be 10%–25% [6, 12] and 20%–43% [6, 13, 55–57], respectively. This high rate of HCC recurrence presents an important clinical challenge, and appropriate treatment is crucial in improving long-term outcomes after treatments [58]. Although many studies have compared different RFA devices and systems in the treatment of initial HCC, similar studies focusing on recurrent tumors are rare; to our knowledge, there is no published randomized controlled study comparing different RFA systems in the treatment of recurrent HCC.

In our study, total RF energy delivery and energy delivery per unit time of the TICW-RFA group were smaller than those of the SC-RFA group, which resulted in a higher minimum diameter per energy in the TICW-RFA group than in the SC-RFA group (p < 0.001). These results of TICW-RFA could be attributed to better concentration of RF energy between the electrodes and also improved electrical conductivity with a saline infusion into the tissue. Electrically, bipolar RFA is able to produce a better concentration of RF energy between the electrodes than monopolar RFA, as it converges energy centripetally from the periphery, while the RF current flows centrifugally in monopolar RFA [33]. Although the disadvantage of conventional bipolar RFA is the possibility of overheating that may lead to charring and insufficient RF energy delivery, cold saline infusion of the ICW electrode used is one way to overcome this
problem by preserving thermal and electrical conductivity [59]. Hypothetically, the saline infusion can increase the tissue’s internal pressure that may lead to spreading the cancer cells around the ablation zone, which is one of the proposed mechanisms of AIR [60]; however, no AIR occurred in our TICW-RFA group. In addition to the electrical advantages of bipolar RFA with ICW electrodes, TICW in our study, ICW-RFA using twin electrodes, was able to provide a clinically meaningful advantage of the capability of the “no-touch” technique [61]. Recent studies demonstrated that no-touch RFA in multi-bipolar mode was able to provide better local tumor control for HCC <5 cm than monopolar RFA [52, 62]. Furthermore, Chang et al. [37] recently compared the bipolar RFA and the multi-monopolar RFA, similar to our study, in treatment for small initial HCC, and showed the promising potential of the better tumor control with bipolar RFA. While Chang et al. [37] used switching bipolar mode with three single ICW electrodes, the TICW electrode used in our study, consisted of two active tips and cost the same as one single ICW electrode. Therefore, we believe that bipolar-RFA with TICW electrodes could be a promising method with high-cost effectiveness for obtaining local tumor control for small HCC, compared with monopolar RFA or multi-bipolar RFA with multiple (3–4) electrodes.

In a clinical setting, based on our results, the TICW-RFA and the SC-RFA can be considered comparable treatment options for the treatment of intrahepatic recurrence of HCC, both with similar safety profile and therapeutic efficacy. However, TICW-RFA may help in some clinical scenarios (Table 3). In patients with coagulopathy, a fewer number of electrodes in TICW-RFA may lower the risk of bleeding. TICW-RFA may ensure less thermal damage to adjacent organs for tumors close to the gallbladder or the colon by concentrating the RF energy only between the electrodes. In patients with metallic implants including a pacemaker, electric interference between the device and the RFA system is prevented in TICW-RFA since the RF current flow does not involve a grounding pad but stays only between the electrodes. On the other hand, SC-RFA has geometric advantages over TICW-RFA since it can create an ablation zone according to tumor shape and does not require strict orientation of electrodes.

There are some limitations to our study. First, this study involved a relatively small number of the study population with an intermediate follow-up period. A statistical comparison between the two systems is warranted for a future fully powered randomized controlled trial. Second, as mentioned above, this study included small-sized tumors that may have underestimated the ablative capacities of the two RFA systems. Third, the tumors in our study were most likely heterogeneous in terms of oncological behavior due to relatively broad indications for RFA for the treatment of recurrent HCC in our institution. Although our study, because it was a randomized controlled trial, necessitated reflecting clinical practice as it is, there may be a limitation in generalizing our experience to other institutions or nations.

Table 3. Comparison of potential benefits of TICW-RFA and SC-RFA.

|                  | TICW-RFA                                           | SC-RFA                                         |
|------------------|----------------------------------------------------|------------------------------------------------|
| Effect of number of electrodes | Decreases risk of bleeding | Able to create an ablation zone according to shape |
| Effect of RF system design   | No electric interference with metallic implant     | Does not require strict orientation of electrodes |
|                         | Less adjacent organ injury                         |                                                 |
| Effect of saline infusion  | Improves thermal and electrical conductance in dehydrated tissue |                                                 |

https://doi.org/10.1371/journal.pone.0239733.t003
In conclusion, in this single-center randomized controlled study from a Korean tertiary referral hospital, TICW-RFA demonstrated similar therapeutic efficacy and safety profile for recurrent HCC after locoregional treatment compared with SC-RFA.

Supporting information

S1 Checklist. CONSORT checklist.
(DOC)

S1 File. Full study protocol in Korean.
(DOC)

S2 File. Summarized study protocol in English.
(DOC)

S3 File. Anonymized raw data.
(XLSX)

Author Contributions

Conceptualization: Jeong Min Lee, Jung-Hwan Yoon, Yoon Jun Kim, Jeong-Hoon Lee, Su Jong Yu, Eun Ju Cho.

Data curation: Jae Won Choi.

Formal analysis: Jae Won Choi, Jeong Min Lee.

Funding acquisition: Jeong Min Lee.

Investigation: Jae Won Choi, Jeong Min Lee, Dong Ho Lee, Jung-Hwan Yoon, Yoon Jun Kim, Jeong-Hoon Lee, Su Jong Yu, Eun Ju Cho.

Methodology: Jae Won Choi, Jeong Min Lee, Dong Ho Lee.

Project administration: Jeong Min Lee.

Resources: Jeong Min Lee.

Supervision: Jeong Min Lee.

Validation: Jae Won Choi.

Visualization: Jae Won Choi.

Writing – original draft: Jae Won Choi, Jeong Min Lee.

Writing – review & editing: Jae Won Choi, Jeong Min Lee, Dong Ho Lee.

References

1. European Association for the Study of the Liver. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69: 182–236. https://doi.org/10.1016/j.jhep.2018.03.019 PMID: 29628281

2. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018; 67: 358–380. https://doi.org/10.1002/hep.29086 PMID: 29130846

3. Omata M, Cheng A-L, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017; 11: 317–370. https://doi.org/10.1007/s12072-017-9799-9 PMID: 28620797
4. Rossi S, Ravetta V, Rosa L, Ghittoni G, Viera FT, Garbagnati F, et al. Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatoacellular carcinomas: a long-term cohort study. Hepatology. 2011; 53: 136–147. https://doi.org/10.1002/hep.23965 PMID: 20967759

5. Nishikawa H, Osaki Y, Iguchi E, Takeda H, Ohara Y, Sakamoto A, et al. Percutaneous radiofrequency ablation therapy for recurrent hepatoacellular carcinoma. Anticancer Res. 2012; 32: 5059–5065. PMID: 23155279

6. Lee DH, Lee JM, Lee JY, Kim SH, Han JK, Choi BI. Radiofrequency ablation for intrahepatic recurrent hepatoacellular carcinoma: long-term results and prognostic factors in 168 patients with cirrhosis. Cardiovasc Intervent Radiol. 2014; 37: 705–715. https://doi.org/10.1007/s00270-013-0708-x PMID: 23912493

7. Kim Y-S, Lim HK, Rhim H, Lee MW, Choi D, Lee WJ, et al. Ten-year outcomes of percutaneous radiofrequenciy ablation as first-line therapy of early hepatoacellular carcinoma: analysis of prognostic factors. J Hepatol. 2013; 58: 89–97. https://doi.org/10.1016/j.jhep.2012.09.020 PMID: 2302309

8. N’Kontchou G, Mahamoudi A, Aout M, Ganne-Carrié N, Grando V, Codec E, et al. Radiofrequency ablation of hepatoacellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol. 2007; 188: 480–488. https://doi.org/10.2214/AJR.05.2079 PMID: 17242258

9. Lee DH, Lee JM, Lee JY, Kim SH, Yoon JH, Kim YJ, et al. Radiofrequency ablation of hepatoacellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis. Radiology. 2014; 270: 900–909. https://doi.org/10.1148/radiol.13130940 PMID: 24475823

10. Nakazawa T, Kokusu S, Shibuya A, Ono K, Watanabe M, Hidaka H, et al. Radiofrequency ablation of hepatoacellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol. 2007; 188: 480–488. https://doi.org/10.2214/AJR.05.2079 PMID: 17242258

11. Kim Y-S, Lee WJ, Rhim H, Lim HK, Choi D, Lee JY. The minimal ablative margin of radiofrequency ablation of hepatoacellular carcinoma (>2 and <5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol. 2010; 195: 758–765. https://doi.org/10.2214/AJR.09.2954 PMID: 20729457

12. Yoon JH, Lee JM, Klotz E, Woo H, Yu MH, Joo I, et al. Prediction of Local Tumor Progression after Radiofrequency Ablation (RFA) of Hepatocellular Carcinoma by Assessment of Ablative Margin Using Pre-RFA MRI and Post-RFA CT Registration. Korean J Radiol. 2018; 19: 1053. https://doi.org/10.3348/kjr.2018.19.6.1053 PMID: 30386137

13. Imai K, Beppu T, Chikamoto A, Mima K, Okabe H, Hayashi H, et al. Salvage treatment for local recurrence of hepatoacellular carcinoma after local ablation therapy. Hepatol Res. 2014; 44: E335–45. https://doi.org/10.1111/hepr.12313 PMID: 24552247

14. Lam VW-T, Ng KK-C, Chok KS-H, Cheung T-T, Yuen J, Tung H, et al. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatoacellular carcinoma. J Am Coll Surg. 2008; 207: 20–29. https://doi.org/10.1016/j.jamcollsurg.2008.01.020 PMID: 18589377

15. Lam VW-T, Ng KK, Chok KS-H, Cheung T-T, Yuen J, Tung H, et al. Incomplete ablation after radiofrequency ablation of hepatoacellular carcinoma: analysis of risk factors and prognostic factors. Ann Surg Oncol. 2008; 15: 782–790. https://doi.org/10.1245/s10434-007-9733-9 PMID: 18095030

16. Rozenblum N, Zeira E, Scaiwicz V, Bulvik B, Gourievitch S, Yotvat H, et al. Oncogenesis: An “Off-Target” Effect of Radiofrequency Ablation. Radiology. 2015; 276: 426–432. https://doi.org/10.1148/radiol.201514695 PMID: 26203709

17. Ahmed M, Kumar G, Moussa M, Wang Y, Rozenblum N, Galun E, et al. Hepatic Radiofrequency Ablation-induced Stimulation of Distant Tumor Growth Is Suppressed by c-Met Inhibition. Radiology. 2016; 279: 103–117. https://doi.org/10.1148/radiol.2015150088 PMID: 26418615

18. Kong J, Kong J, Pan B, Ke S, Dong S, Li X, et al. Insufficient radiofrequency ablation promotes angio genesis of residual hepatoacellular carcinoma via HIF-1α/VEGFA. PLoS One. 2012; 7: e37266. https://doi.org/10.1371/journal.pone.0037266 PMID: 22615958

19. Nijkamp MW, van der Bilt JDW, de Bruijn MT, Molenaar IQ, Voest EE, van Diest PJ, et al. Accelerated perinecrotic outgrowth of colorectal liver metastases following radiofrequency ablation is a hypoxia-driven phenomenon. Ann Surg. 2009; 249: 814–823. https://doi.org/10.1097/SLA.0b013e3181a38ef5 PMID: 19387320

20. Zen C, Zen Y, Mitry RR, Corbel D, Karbanová J, O’Grady J, et al. Mixed phenotype hepatoacellular carcinoma after transarterial chemoembolization and liver transplantation. Liver Transpl. 2011; 17: 943–954. https://doi.org/10.1002/lt.22314 PMID: 21491582

21. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, et al. Transcatheter arterial chemoembolization (TACE) in hepatoacellular carcinoma (HCC): the role of angio genesis and invasiveness. Am J Gastroenterol. 2008; 103: 914–921. https://doi.org/10.1111/j.1572-0241.2007.01712.x PMID: 18177453
22. Lee JM, Han JK, Kim HC, Choi YH, Kim SH, Choi JY, et al. Switching monopolar radiofrequency ablation technique using multiple, internally cooled electrodes and a multichannel generator: ex vivo and in vivo pilot study. Invest Radiol. 2007; 42: 163–171. https://doi.org/10.1097/RLI.0b013e31802e83e7 PMID: 17287646

23. Laeseke PF, Frey TM, Brace CL, Sampson LA, Winter TC 3rd, Ketzler JR, et al. Multiple-electrode radiofrequency ablation of hepatic malignancies: initial clinical experience. AJR Am J Roentgenol. 2007; 188: 1485–1494. https://doi.org/10.2214/AJR.06.1004 PMID: 17515366

24. Mulier S, Miao Y, Mulier P, Dupas B, Pereira P, de Baere T, et al. Electrodes and multiple electrode systems for radiofrequency ablation: a proposal for updated terminology. Eur Radiol. 2005; 15: 798–808. https://doi.org/10.1007/s00330-004-2584-x PMID: 15711846

25. Yoon JH, Lee JM, Woo S, Hwang EJ, Hwang I, Choi W, et al. Switching bipolar hepatic radiofrequency ablation using internally cooled wet electrodes: comparison with consecutive monopolar and switching monopolar modes. Br J Radiol. 2015; 88: 20140468. https://doi.org/10.1259/bjr.20140468 PMID: 25873479

26. Martin RCG, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol. 2010; 17: 171–178. https://doi.org/10.1245/s10434-009-0686-z PMID: 19707829

27. Poulou LS, Botsa E, Thanou I, Ziakas PD, Thanos L. Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Hepatol. 2015; 7: 1054–1063. https://doi.org/10.4255/wjh.v7.i8.1054 PMID: 26032394

28. Ding J, Jing X, Liu J, Wang Y, Wang F, Wang Y, et al. Comparison of two different thermal techniques for the treatment of hepatocellular carcinoma. Eur J Radiol. 2013; 82: 1379–1384. https://doi.org/10.1016/j.ejrad.2013.04.025 PMID: 23726122

29. Yamakado K, Nakatsuka A, Ohmori S, Shiraki K, Nakano T, Ikoma J, et al. Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: treatment response based on tumor size and morphology. J Vasc Interv Radiol. 2002; 13: 1225–1232. https://doi.org/10.1016/s1051-0443(02)01969-1 PMID: 12471186

30. Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology. 2009; 252: 905–913. https://doi.org/10.1148/ radiol.2523081676 PMID: 19567647

31. Feng X, Xu R, Du X, Dou K, Qin X, Xu J, et al. Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study. Am J Gastroenterol. 2014; 109: 1891–1899. https://doi.org/10.1038/ajg.2014.343 PMID: 25403366

32. Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017; 66: 545–551. https://doi.org/10.1016/j.jhep.2016.10.029 PMID: 27816492

33. Lee DH, Lee JM. Recent Advances in the Image-Guided Tumor Ablation of Liver Malignancies: Radiofrequency Ablation with Multiple Electrodes, Real-Time Multimodality Fusion Imaging, and New Energy Sources. Korean J Radiol. 2018; 19: 545–559. https://doi.org/10.3348/kjr.2018.19.4.545 PMID: 29962861

34. Lee JM, Han JK, Kim SH, Lee JY, Shin KS, Han CJ, et al. Optimization of wet radiofrequency ablation using a perfused-cooled electrode: a comparative study in ex vivo bovine livers. Korean J Radiol. 2004; 5: 250–257. https://doi.org/10.3348/kjr.2004.5.4.250 PMID: 15637475

35. Kröcker J, Xu S, Venkatesan A, Locklin JK, Amalou H, Glossop N, et al. Clinical utility of real-time fusion guidance for biopsy and ablation. J Vasc Interv Radiol. 2011; 22: 515–524. https://doi.org/10.1016/j.jvir.2010.10.033 PMID: 21354816

36. Kim JH, Kim PN, Won HJ, Shin YM. Percutaneous radiofrequency ablation using internally cooled wet electrodes for the treatment of hepatocellular carcinoma. AJR Am J Roentgenol. 2012; 199: 471–476. https://doi.org/10.2214/AJR.11.6583 PMID: 22268196

37. Chang W, Lee JM, Lee DH, Yoon JH, Kim YJ, Yoon JH, et al. Comparison of switching bipolar ablation with multiple cooled wet electrodes and switching monopolar ablation with separable clustered electrode in treatment of small hepatocellular carcinoma: A randomized controlled trial. PLoS One. 2018; 13: e0192173. https://doi.org/10.1371/journal.pone.0192173 PMID: 29420589

38. Woo S, Lee JM, Yoon JH, Joo I, Kim SH, Lee JY, et al. Small- and medium-sized hepatocellular carcinomas: monopolar radiofrequency ablation with a multiple-electrode switching system-mid-term results. Radiology. 2013; 268: 589–600. https://doi.org/10.1148/radiol.13121736 PMID: 23513241

39. Choi JW, Lee JM, Lee DH, Yoon J-H, Suh K-S, Yoon J-H, et al. Switching Monopolar Radiofrequency Ablation Using a Separable Cluster Electrode in Patients with Hepatocellular Carcinoma: A Prospective Study. PLoS One. 2016; 11: e0161980. https://doi.org/10.1371/journal.pone.0161980 PMID: 27575787
40. Ahn SJ, Lee JM, Lee DH, Lee SM, Yoon J-H, Kim YJ, et al. Real-time US-CT/MR fusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinoma. J Hepatol. 2017; 66: 347–354. https://doi.org/10.1016/j.jhep.2016.09.003 PMID: 27650284

41. Lee MW. Fusion imaging of real-time ultrasonography with CT or MRI for hepatic intervention. Ultrasound. 2014; 33: 227–239. https://doi.org/10.14366/usg.14021 PMID: 25036756

42. Nam SY, Rhim H, Kang TW, Lee MW, Kim Y-S, Choi D, et al. Percutaneous radiofrequency ablation for hepatic tumors abutting the diaphragm: clinical assessment of the heat-sink effect of artificial asicites. AJR Am J Roentgenol. 2010; 194: W227–31. https://doi.org/10.2214/AJR.09.2979 PMID: 20093579

43. Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria—a 10-year update. Radiology. 2014; 273: 241–260. https://doi.org/10.1148/radiol.14132958 PMID: 24927329

44. Choi H, Loyer EM, Dubrow RA, Kaur H, David CL, Huang S, et al. Radio-frequency ablation of liver tumors: assessment of therapeutic response and complications. Radiographics. 2001; 21 Spec No: S41–S4. https://doi.org/10.1148/radiographics.21.suppl_1.g01oc08s41 PMID: 11598247

45. Sacks D, McClenny TE, Cardella JF, Lewis CA. Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol. 2003; 14: S199–202. https://doi.org/10.1097/01.rvi.0000094584.83406.3e PMID: 14514818

46. Kim JH, Won HJ, Shin YM, Kim K-A, Kim PN. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. AJR Am J Roentgenol. 2011; 196: W205–9. https://doi.org/10.2214/AJR.10.4937 PMID: 21257684

47. Lim HK, Choi D, Lee WJ, Kim SH, Lee SJ, Jang HJ, et al. Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with follow-up multiphase helical CT. Radiology. 2001; 221: 447–454. https://doi.org/10.1148/radiology.2212010446 PMID: 11687689

48. Kang TW, Lim HK, Lee MW, Kim Y-S, Rhim H, Lee WJ, et al. Aggressive Intrasegmental Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation: Risk Factors and Clinical Significance. Radiology. 2015; 276: 274–285. https://doi.org/10.1148/radiol.15141215 PMID: 25734550

49. Yang W, Chen MH, Yin SS, Yan K, Gao W, Wang YB, et al. Radiofrequency ablation of recurrent hepatocellular carcinoma after hepatectomy: therapeutic efficacy on early- and late-phase recurrence. AJR Am J Roentgenol. 2006; 186: S275–83. https://doi.org/10.2214/AJR.04.1573 PMID: 16632688

50. Lee JM, Han JK, Kim SH, Han CJ, An SK, Lee JY, et al. Wet radio-frequency ablation using multiple electrodes: comparative study of bipolar versus monopolar modes in the bovine liver. Eur J Radiol. 2005; 54: 408–417. https://doi.org/10.1016/j.ejrad.2004.06.004 PMID: 15899344

51. Kim JH, Kim PN, Won HJ, Shin YM. Percutaneous radiofrequency ablation with internally cooled wet electrodes for small subphrenic hepatocellular carcinomas. J Vasc Interv Radiol. 2013; 24: 351–356. https://doi.org/10.1016/j.jvir.2012.11.025 PMID: 23433411

52. Hocquet J, Aube C, Rode A, Cartier V, Sutter O, Manichon AF, et al. Comparison of no-touch multipolar vs. monopolar radiofrequency ablation for small HCC. J Hepatol. 2017; 66: 67–74. https://doi.org/10.1016/j.jhep.2016.07.010 PMID: 27422750

53. Lee J, Lee JM, Yoon J-H, Lee JY, Kim SH, Lee JE, et al. Percutaneous radiofrequency ablation with multiple electrodes for medium-sized hepatocellular carcinomas. Korean J Radiol. 2012; 13: 34–43. https://doi.org/10.3348/kjr.2012.13.1.34 PMID: 22247634

54. Mima K, Hayashi H, Imai K, Kuroki H, Nakagawa S, Okabe H, et al. High CD44s expression is associated with the EMT expression profile and intrahepatic dissemination of hepatocellular carcinoma after local ablation therapy. J Hepatobiliary Pancreat Sci. 2013; 20: 429–434. https://doi.org/10.1007/s00534-012-0580-0 PMID: 23238743

55. Choi D, Lim HK, Rhim H, Kim Y-S, Yoo BC, Paik SW, et al. Percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma after hepatectomy: long-term results and prognostic factors. Ann Surg Oncol. 2007; 14: 2319–2329. https://doi.org/10.1245/s10434-006-9220-8 PMID: 17522947

56. Peng Z-W, Zhang Y-J, Liang H-H, Lin X-J, Guo R-P, Chen M-S. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology. 2012; 262: 689–700. https://doi.org/10.1148/radiol.11110637 PMID: 22157201

57. Chan ACY, Chan SC, Chok KSH, Cheung TT, Chiu DW, Poon RTP, et al. Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency? Liver Transpl. 2013; 19: 411–419. https://doi.org/10.1002/lt.23605 PMID: 23447480

58. Chen R, Gan Y, Ge N, Chen Y, Wang Y, Zhang B, et al. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study. J Vasc Interv Radiol. 2016; 27: 1829–1836. https://doi.org/10.1016/j.jvir.2016.06.010 PMID: 27553917
59. Lee JM, Kim SH, Han JK, Sohn KL, Choi BI. Ex Vivo Experiment of Saline-Enhanced Hepatic Bipolar Radiofrequency Ablation with a Perfused Needle Electrode: Comparison with Conventional Monopolar and Simultaneous Monopolar Modes. CardioVascular and Interventional Radiology. 2005. pp. 338–345. https://doi.org/10.1007/s00270-004-0177-3 PMID: 15789259

60. Kang TW, Lim HK, Cha DI. Aggressive tumor recurrence after radiofrequency ablation for hepatocellular carcinoma. Clin Mol Hepatol. 2017; 23: 95–101. https://doi.org/10.3350/cmh.2017.0006 PMID: 28349677

61. Chang W, Lee JM, Lee SM, Han JK. No-Touch Radiofrequency Ablation: A Comparison of Switching Bipolar and Switching Monopolar Ablation in Bovine Liver. Korean J Radiol. 2017; 18: 279–288. https://doi.org/10.3348/kjr.2017.18.2.279 PMID: 28246508

62. Seror O, N'Kontchou G, Van Nhieu JT, Rabahi Y, Nahon P, Laurent A, et al. Histopathologic comparison of monopolar versus no-touch multipolar radiofrequency ablation to treat hepatocellular carcinoma within Milan criteria. J Vasc Interv Radiol. 2014; 25: 599–607. https://doi.org/10.1016/j.jvir.2013.11.025 PMID: 24529547